ipratropium bromide

CLINICAL USE


Anticholinergic bronchodilator:Reversible airways obstruction, particularly in COPD

DOSE IN NORMAL RENAL FUNCTION

Nebuliser solution: 250–500 micrograms 3– 4 times dailyInhaler: 20–80 micrograms 3–4 times daily

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :430.4
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :<20
  • %Excreted unchanged in urine &nbsp &nbsp : <1
  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :4.6
  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :1.6/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF/high flux &nbsp :Not dialysed. Dose as in normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • None known

    ADMINISTRATION

    Reconstition

    Route

    Inhaled

    Rate of Administration

    Nebuliser: according to nebuliser

    Comments

    The dose of nebuliser solution may need to be diluted in order to obtain a final volume suitable for the nebuliserSterile sodium chloride 0.9% should be used if dilution is required

    OTHER INFORMATION

    Following inhalation, only a small amount of ipratropium reaches the systemic circulation. Any swallowed drug is poorly absorbed from the GI tract